This assumption is strongly supported by our previous studies on breast cancer patients, in which we already showed that preferentially semi-mesenchymal and potentially platinum-resistant (ERCC1-expressing) CTCs remain after neoadjuvant chemotherapy [54]. This evidence concerns the gene ERCC1 and breast carcinoma.